The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties
Open accessPublished version of a preprint
Abstract
Oncogenic tyrosine kinase fusions involving the anaplastic lymphoma kinase (ALK) are detected in numerous tumor types. Although more than 30 distinct 5′ fusion partner genes have been reported, treatment of ALK-rearranged cancers is decided without regard to which 5′ partner is present. There is little data addressing how the 5′ partner affects the biology of the fusion or responsiveness to ALK tyrosine kinase inhibitors (TKI). On the basis of the hypothesis that the 5′ partner influences the intrinsic properties of the fusion protein, cellular functions that impact oncogenic potential, and sensitivity to ALK TKIs, clonal 3T3 cell lines stably expressing seven different ALK fusion variants were generated. Biochemical and cellular assays were used to assess the efficacy of various ALK TKIs in clinical use, transformative phenotypes, and biochemical properties of each fusion. All seven ALK fusions induced focus formation and colonies in soft agar, albeit to varying degrees. IC50s were calculated for different ALK TKIs (crizotinib, ensartinib, alectinib, lorlatinib) and consistent differences (5–10 fold) in drug sensitivity were noted across the seven ALK fusions tested. Finally, biochemical analyses revealed negative correlations between kinase activity and protein stability. These results demonstrate that the 5′ fusion partner plays an important biological role that affects sensitivity to ALK TKIs. Implications: This study shows that the 5′ ALK fusion partner influences ALK TKI drug sensitivity. As many other kinase fusions are found in numerous cancers, often with overlapping fusion partners, these studies have ramifications for other kinase-driven malignancies. Mol Cancer Res; 16(11); 1724–36. ©2018 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the PRKAR1A-ALK fusion was consistently demonstrated to be less sensitive to first, second and third generation ALK TKIs48.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Pankov, R. G., & Yamada, K. M. (2002) · Journal of Cell Science · doi:10.1242/jcs.00059 · Cited by 2,055
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
Self-citationGainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo‐Jack, I., Gadgeel, S. M., Schultz, K. R., Singh, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0596 · Cited by 1,180
cAMP-DEPENDENT PROTEIN KINASE: FRAMEWORK FOR A DIVERSE FAMILY OF REGULATORY ENZYMES
Taylor, S. S., Buechler, J. A., & Yonemoto, W. M. (1990) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.59.070190.004543 · Cited by 1,144
Doebele, R. C., Pilling, A. B., Aisner, D. L., Kutateladze, T. G., Le, A. T., Weickhardt, A. J., Kondo, K. L., Linderman, D. J., Heasley, L. E., Franklin, W. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2906 · Cited by 1,083
Melnick, A. M., & Licht, J. D. (1999) · Blood · doi:10.1182/blood.v93.10.3167.410k44_3167_3215 · Cited by 1,029
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Janoueix‐Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008) · Nature · doi:10.1038/nature07398 · Cited by 893
Cited by
Sorted by citations
Items 101–108 of 108
Prevailing challenges in companion diagnostic test development for lung cancer
Luca, S. D., Celi, A., Cioce, A., Diluvio, A., Ali, M., Montella, M., Corte, C. M. D., Morgillo, F., Fiorelli, A., Alì, G., et al. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2575018
Etude des résistances aux inhibiteurs d’ALK dans les LAGC ALK+
Vasseur, D. (2023) · theses.fr (ABES) · doi:10.70675/f61106c4z7744z4662z8df7z4c6f885a65cf
RET fusion partners dictate oncogenic potential in undifferentiated spindle cell sarcomas
Gui, Q., Zhang, Y., Yang, M., Liang, R., Huang, M., Yang, X., Chen, N., Chen, X., Wu, M., Chen, H., et al. (2026) · Cancer Biology & Therapy · doi:10.1080/15384047.2026.2683190
Self-citationWu, T.-Y., Liu, N.-T., Wu, Y., & Liu, C. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109548
Zihua, G. U. A. N., Liu, J., Yu, W., Wang, X., & Zhang, X. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1832676
Abdullah, A., Talukder, M. E. K., Shahir, N. F., & Arafat, M. T. (2026) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2026.109246
Zhang, M., Feng, Y., Du, X., Qu, C., Meng, M., 冶美英, Liang, M., Yang, Z., Gong, W., Ma, X., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1890263
Metadata
- Authors
- Childress, M. A., Himmelberg, S. M., Chen, H., Deng, W., Davies, M. A., & Lovly, C. M.
- Affiliations
- Vanderbilt University (US)
- Vanderbilt University Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Lovly, Christine M.
- Venue
- Molecular Cancer Research
- Published
- 2018-11-01
- Volume
- 16
- Issue
- 11
- Pages
- 1724-1736
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- PMC
- PMC6214753
- OpenAlex
- W2839057355
- Cited by
- 108
- References
- 61
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 13 · 2023: 14 · 2022: 17 · 2021: 20 · 2020: 12 · 2019: 10 · 2018: 2
- FWCI
- 8.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- For the Linds Foundation
- International Association for the Study of Lung Cancer (IASLC)
- HHS | NIH | National Cancer Institute (NCI) (CA009592, CA16672, R01CA121210, CA213744-02)
- TJ Martell Foundation
- American Cancer Society (ACS) (IRG-58-009-54)
- Damon Runyon Cancer Research Foundation (Damon Runyon)
- LUNGevity Foundation
- V Foundation for Cancer Research (V Foundation)
- AACR-Genentech Career Development Award (15-20-18-LOVL)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- ALK fusion partners, anaplastic lymphoma kinase, tyrosine kinase inhibitors, drug sensitivity, kinase activity, protein stability, crizotinib, ensartinib, alectinib, lorlatinib, oncogenic transformation, soft agar colony formation
- MeSH terms
- Anaplastic Lymphoma Kinase, Animals, Phenotype, Oncogene Proteins, Fusion, NIH 3T3 Cells, Cell Line, Tumor, Protein Kinase Inhibitors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
